We outline the molecular pathogenesis and splicing biology of DMD and SMA, explain the design and use of antisense oligonucleotides in therapeutic exon skipping and exon inclusion respectively, and discuss the delivery of oligonucleotide drugs to muscle, heart and the central nervous system. This evidence concerns the gene DMD and proximal spinal muscular atrophy.